These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8420593

  • 21. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
    Abi-Saab W, Seibyl JP, D'Souza DC, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH.
    Psychopharmacology (Berl); 2002 Jun; 162(1):55-62. PubMed ID: 12107618
    [Abstract] [Full Text] [Related]

  • 22. 5-HT2A/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).
    Tucci MC, Dvorkin-Gheva A, Johnson E, Wong M, Szechtman H.
    Behav Brain Res; 2015 Feb 15; 279():211-7. PubMed ID: 25449840
    [Abstract] [Full Text] [Related]

  • 23. Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls.
    Ho Pian KL, Westenberg HG, den Boer JA, de Bruin WI, van Rijk PP.
    Biol Psychiatry; 1998 Sep 01; 44(5):367-70. PubMed ID: 9755360
    [Abstract] [Full Text] [Related]

  • 24. Serotonin dysregulation in adolescents with major depression: hormone response to meta-chlorophenylpiperazine (mCPP) infusion.
    Ghaziuddin N, King CA, Welch KB, Zaccagnini J, Weidmer-Mikhail E, Mellow AM, Ghaziuddin M, Greden JF.
    Psychiatry Res; 2000 Sep 11; 95(3):183-94. PubMed ID: 10974357
    [Abstract] [Full Text] [Related]

  • 25. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats.
    Baumann MH, Rutter JJ, Auerbach SB.
    Neuropharmacology; 1993 Dec 11; 32(12):1381-6. PubMed ID: 8152528
    [Abstract] [Full Text] [Related]

  • 26. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers.
    Silverstone PH, Cowen PJ.
    Biol Psychiatry; 1994 Sep 01; 36(5):309-16. PubMed ID: 7993957
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile.
    Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML.
    Pharmacopsychiatry; 2004 Jul 01; 37(4):180-8. PubMed ID: 15467976
    [Abstract] [Full Text] [Related]

  • 28. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP).
    Callahan PM, Cunningham KA.
    Eur J Pharmacol; 1994 May 12; 257(1-2):27-38. PubMed ID: 8082704
    [Abstract] [Full Text] [Related]

  • 29. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
    Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J.
    Neuropsychobiology; 2004 May 12; 50(3):200-5. PubMed ID: 15365215
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine.
    Fiorella D, Rabin RA, Winter JC.
    Psychopharmacology (Berl); 1995 May 12; 119(2):222-30. PubMed ID: 7659770
    [Abstract] [Full Text] [Related]

  • 36. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder.
    Pian KL, Westenberg HG, van Megen HJ, den Boer JA.
    Psychopharmacology (Berl); 1998 Dec 12; 140(3):365-70. PubMed ID: 9877016
    [Abstract] [Full Text] [Related]

  • 37. Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression.
    Klaassen T, Riedel WJ, van Praag HM, Menheere PP, Griez E.
    Psychiatry Res; 2002 Dec 15; 113(1-2):29-40. PubMed ID: 12467943
    [Abstract] [Full Text] [Related]

  • 38. Fear extinction in an obsessive-compulsive disorder animal model: Influence of sex and estrous cycle.
    Reimer AE, de Oliveira AR, Diniz JB, Hoexter MQ, Miguel EC, Milad MR, Brandão ML.
    Neuropharmacology; 2018 Mar 15; 131():104-115. PubMed ID: 29225044
    [Abstract] [Full Text] [Related]

  • 39. Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine.
    Wetzler S, Asnis GM, DeLecuona JM, Kalus O.
    Psychiatry Res; 1996 Sep 27; 64(2):77-82. PubMed ID: 8912948
    [Abstract] [Full Text] [Related]

  • 40. The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study.
    Leone M, Attanasio A, Croci D, Filippini G, D'Amico D, Grazzi L, Nespolo A, Bussone G.
    Neurology; 2000 Jul 12; 55(1):136-9. PubMed ID: 10891925
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.